TABLE 1.
Main compounds under development or recently approved for the treatment of MRSA infections
| Antimicrobial groupd | Compound name(s)c | Disease(s) treatedb | Approved for MRSA treatmenta |
|---|---|---|---|
| New antibiotics | Dalbavancin | ABSSSIs | N |
| Oritavancin | SSTIs | N | |
| Telavancin | SSTIs and pneumonia | Y | |
| TD-1792 | SSTIs and ABSSSIs | N | |
| Ceftaroline | CAP and ABSSSIs | Y | |
| Ceftobiprole | CAP and HAP | Y | |
| Iclaprim | SSTIs and pneumonia | N | |
| Tedizolid | ABSSSIs | Y | |
| Radezolid | Acne vulgaris and bacterial vaginosis | N | |
| Eravacycline | Intraabdominal and urinary infections | Y | |
| Omadacycline | ABSSSIs and CAP | Y | |
| Delafloxacin | SSTIs | Y | |
| Zabofloxacin | CAP and chronic obstructive pulmonary disease | N | |
| Nemonoxacin | CAP | N | |
| Retapamulin | CAP and ABSSSIs | Y | |
| Lefamulin | CAP and ABSSSIs | N | |
| Anti-persister/SCV bacteria | CD437 and CD1530 | Chronic and recurrent infections | N |
| Daunorubicin, ketoconazole, rifapentine, and sitafloxacin | Chronic and recurrent infections | N | |
| Vaccines | d-Alanine auxotrophic live vaccine | Sepsis | N |
| Passive immunization | MAbs (alpha toxin) | Pneumonia | N |
| MAbs (enterotoxin K) | Sepsis | N | |
| AMPs | Aurein peptides | Skin infections | N |
a
Y, yes; N, no.
b
ABSSSI, acute bacterial skin and skin structure infection; SSTI, skin and soft tissue infections; CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia.
c
MAb, monoclonal antibody.
d
SCV, small-colony variant; AMP, antimicrobial peptide.